

May 26, 2020



## Rigel to Present at the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 26, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 p.m. Eastern Time.

To access the live and subsequently archived webcast, go to the Investor Relations section of the company's website at [www.rigel.com](http://www.rigel.com). Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

### **About Rigel ([www.rigel.com](http://www.rigel.com))**

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE<sup>®</sup> (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product has been approved by the European Commission for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments and will be marketed in Europe under the name TAVLESSE<sup>®</sup> (fostamatinib).

Rigel's clinical programs include a Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (AIHA); a completed Phase 1 study of R835<sup>1</sup>, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of R552<sup>1</sup>, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners Aclaris Therapeutics, AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

**Please see [www.TAVALISSE.com](http://www.TAVALISSE.com) for the full Prescribing Information.**

<sup>1</sup>This product candidate is investigational and has not been established safe or effective by the U.S. Food and Drug Administration (FDA) or any regulatory authority.

Contact: David Burke  
Phone: 650.624.1232  
Email: [dburke@rigel.com](mailto:dburke@rigel.com)



View original content to download multimedia <http://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-virtual-healthcare-conference-301064907.html>

SOURCE Rigel Pharmaceuticals, Inc.